| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.9 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |